Skip to main content
    NanoViricides

    NanoViricides In The News

       IPO-Edge
    Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan
    		 
       Alliance Global Partners
    		 
       Proactive
    NanoViricides files for Rare Pediatric Disease Designation for Measles Drug
    		 
       Proactive
    NanoViricides advances toward fully funded Phase II MPox trial in DRC
    		 
       Anil Diwan on Building Revolutionary Antiviral Therapies
    (Transcript of Podcast)    		 
       NanoViricides receives approval to start Phase II clinical trial of NV-387 for MPox treatment in DRC 
       NNVC: Getting Set for Phase 2 Trial of NV-387 in MPox… 
      NanoViricides’ NV-387 shows potent anti-measles activity, highlighting broad-spectrum potential 
      Dual track clinical development during 2026 
      Broad-Spectrum NV-387 To Enable Emperic Antiviral Treatment - A Revolutionary Prospect Reminiscent of Antibiotics 
       NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC
    May 5, 2025    		 
       New research warns measles could become endemic again in the US as vaccination rates fall
    April 28, 2025    		 
       
      NanoViricides eyes role in US bird flu fight as USDA unveils $100M initiative
    March 28, 2025     		 
      NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials
    Feb. 19, 2025     		 
       NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts
    Feb. 3, 2025    		 
       NanoViricides advances antiviral drug with Phase II Clinical trial to Combat MPox
    		 
       NanoViricides CEO discusses groundbreaking broad-spectrum antiviral treatment 

    		 Bird flu is coming to humans...this treatment is ready! 
       The Wall Street Tranascript, Nanoviricides, Inc 
      Antiviral Drug Development:  
       PODD Interview Written Transcript 
       Nanoviricides Investigates NV-387 for MPOX Treatment Amid Global Outbreak 
        
       NanoViricides is leveraging its unique nanoviricide platform technology to create first-in-class drugs against viruses. 

    		  6-27-2024 Proactive Interview 
       Promising Results Against Multiple Viruses
    Proactive Interview May 9, 2024    		 
       NNVC: Good Superior Model Data News of NV-387 for Influenza A/H3N2 Virus
    May 7, 2024
    		 
       Key Data on Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2
    Jan. 20, 2024
    		 
      NNVC: Inflection Point Reached of Multi-Indications Platform; Re-Initiating With a Buy and $6.50 Price Target
    December 13, 2023
    		 

    		 ProActive Interview
    Nov. 28, 2023    		 
       Dr. Anil Diwan on Fox Business 
       
       
      Dr. Anil R. Diwan Recognized as "Researcher of the year". 
     NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
    April 15, 2014